bivalirudin (Angiomax)

designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition

Also Known As:

Angiomax; Angiomax RTU; BG 8967; BG-8967; BG8967; CTB-001; Hirulog; Hirulog-1; L-leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-; Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen; Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu; Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64); bivalirudin trifluoroacetate

Networked: 1085 relevant articles (159 outcomes, 350 trials/studies)

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - bivalirudin: 1085
  - Serpins: 906
    - Antithrombin Proteins: 6
      - Hirudins: 707
        bivalirudin: 1085
- Peptides: 82426
  - Serpins: 906
    - Antithrombin Proteins: 6
      - Hirudins: 707
        bivalirudin: 1085
  - Peptide Fragments: 373
    - bivalirudin: 1085

Experts

1.	Mehran, Roxana: 102 articles (11/2021 - 09/2005)
2.	Stone, Gregg W: 100 articles (01/2021 - 09/2005)
3.	Lincoff, A Michael: 45 articles (01/2018 - 05/2002)
4.	White, Harvey D: 34 articles (03/2020 - 02/2002)
5.	Lansky, Alexandra J: 31 articles (01/2018 - 05/2006)
6.	Valgimigli, Marco: 28 articles (12/2021 - 02/2011)
7.	Feit, Frederick: 28 articles (07/2016 - 02/2003)
8.	Witzenbichler, Bernhard: 28 articles (02/2016 - 05/2008)
9.	Deliargyris, Efthymios N: 27 articles (01/2020 - 10/2012)
10.	Rao, Sunil V: 26 articles (11/2020 - 05/2007)

Related Diseases

1.	Hemorrhage 12/01/2013 - "Bivalirudin was associated with a dramatically reduced risk of bleeding across all categories of renal dysfunction. " 12/01/2005 - "Bivalirudin provides excellent ischemic protection with a significant reduction of bleeding complications, even in high-risk subgroups." 06/01/2004 - "These results suggest that bivalirudin may be used effectively in patients at very high risk of bleeding with enhanced procedural safety." 01/01/2021 - "The bivalirudin group was associated with a significant reduction in NACEs (12.9% vs 21.5%; P = 0.002) and major bleeding (2.5% vs 8.0%; P = 0.001) versus the UFH group at the end of the 30-day follow-up. " 10/01/2017 - "The present meta-analysis shows that bivalirudin can provide a significant reduction of both access and nonaccess site bleeding in patients undergoing PCI. "
2.	Thrombosis (Thrombus) 07/01/2015 - "Angiography revealed a thrombotic occlusion of the left anterior descending artery, treated successfully with bivalirudin administration, thrombus aspiration and a balloon angioplasty. " 10/01/2008 - "In the bolus bivalirudin group the mean thrombus weight was significantly greater than in all other groups (p-value < 0.01 in all analyses). " 08/01/2022 - "Overall, our study results suggest that bivalirudin is effective for the management of HIT and did not show evidence of in-circuit thrombosis. " 03/01/2015 - "The present study showed similar residual thrombus burden and angiographic indices of MVO immediately after PCI between patients treated with bivalirudin and those treated with UFH." 08/01/2007 - "Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis."
3.	ST Elevation Myocardial Infarction 08/01/2017 - "Trials were included if study patients were undergoing primary PCI for acute ST-segment elevation myocardial infarction and were randomly assigned to bivalirudin or UFH treatment. " 06/01/2017 - "This study aimed to evaluate the effect of prolonged full-dose bivalirudin infusion in real-world population with ST-elevation myocardial infarction (STEMI). " 12/12/2016 - "Several clinical trials have compared the safety and effectiveness of bivalirudin versus UFH during PCI for STEMI, but results have been conflicting. " 10/15/2016 - "ST with bivalirudin was higher with ST-segment elevation myocardial infarction (STEMI) in RCTs (OR 1.51, 95% CI 1.15-1.99) but not in observational studies (p=0.65). " 01/01/2015 - "A meta-analysis of randomised trials comparing bivalirudin and UFH in patients with ACS receiving PCI, with separate analyses in STEMI and NSTE-ACS groups. "
4.	Acute Coronary Syndrome 08/01/2009 - "The objective was to assess the safety and efficacy of bivalirudin monotherapy in patients with high-risk acute coronary syndrome (ACS) presenting to the emergency department (ED). " 01/01/2008 - "In summary, is has been shown that bivalirudin alone is safe and effective in the vast majority of patients suffering from acute coronary syndromes and being treated invasively. " 01/01/2012 - "Randomized trials show improved outcomes among acute coronary syndrome patients treated with bivalirudin. " 01/01/2008 - "Recent trials (ACUITY and HORIZONS studies) added evidence regarding safety and efficacy of bivalirudin use in acute coronary syndromes. " 01/01/2008 - "Safety and efficacy of bivalirudin in acute coronary syndromes."
5.	Myocardial Infarction 12/01/2016 - "Thus, this new promising antithrombotic strategy, based on the intracoronary administration of a bivalirudin loading dose during primary PCI, appeared safe, improved myocardial reperfusion, and mitigated enzymatic myocardial infarct size compared with the standard intravenous protocol. " 10/01/2019 - "We utilized Cochrane Review Manager (RevMan) 5.3 to perform a meta-analysis of seven randomized controlled trials (RCTs) with 22,844 patients to compare bivalirudin to UFH in patients with acute myocardial infarction requiring revascularization. " 03/01/2016 - "The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial." 10/01/2013 - "Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the HORIZONS-AMI trial." 12/01/2010 - "A significant difference in the incidence of postprocedural bleedings was observed between the study groups; bivalirudin use was associated with reduced number of bleedings according to Thrombolysis In Myocardial Infarction criteria. "

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	Glycoproteins (Glycoprotein)
3.	Antithrombins
4.	Platelet Membrane Glycoprotein IIb
5.	Anticoagulants
6.	Thrombin
7.	Clopidogrel (Plavix)
8.	Prasugrel Hydrochloride
9.	Enoxaparin (Lovenox)
10.	Abciximab (ReoPro)

Related Therapies and Procedures

1.	Percutaneous Coronary Intervention
2.	Stents
3.	Therapeutics
4.	Drug Therapy (Chemotherapy)
5.	Catheters

HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Application Error

An application error has occurred and our support engineers have been notified.

Please use the browser "Back" button and try your operation again.

OR if the error persists and you require an email response
please contact us at "cs at curehunter.com":

Your request
The circumstances of the error
Your login id/nickname or email

Return to Top Page